Skip to main content
. Author manuscript; available in PMC: 2016 Mar 15.
Published in final edited form as: Clin Cancer Res. 2015 Jan 21;21(6):1340–1347. doi: 10.1158/1078-0432.CCR-14-1178

Figure 4.

Figure 4

(A–D) Representative IHC for ER and (E–H) for the proliferation marker Ki-67, corresponding to MCF-7 xenografts from mice treated with one dose of (A,E) vehicle, (B,F) 0.05 mg,(C,G) 0.5 mg, or (D,H) 5 mg fulvestrant. The number of cells and the intensity of staining for ER monotonically diminish with increased doses of fulvestrant while the Ki-67 staining remained relatively constant among treatment groups across all doses.